Hot Pursuit     18-Jun-24
Cipla hits record high as UK arm plans to invest additional 3 mln euro in Ethris
The pharma major announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) will invest an additional EUR 3 million in Ethris GmbH, a global leader in delivering mRNAs directly to the respiratory system.

This additional investment through a convertible loan will accelerate Cipla’s participation in the messenger RiboNucleic Acid (mRNA) space.

Earlier, Cipla had invested EUR 15 million in Ethris in 2022. This additional investment reaffirms Cipla’s confidence in Ethris’s proprietary mRNA platform and its potential for patients in emerging markets.

Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments, said the firm.

During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

Umang Vohra, managing director (MD) & global chief executive officer (CEO), Cipla, said, “At Cipla, we strive to dial-up our focus and investment towards innovative modalities and bring new age therapies to emerging countries, including India. The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South.

Dr. Carsten Rudolph, CEO, Ethris, added, “The additional investment by Cipla further validates the broad potential of our platform and Ethris’ innovative approaches to developing respiratory RNA-based medicines. We deeply value this ongoing relationship to bring effective solutions to developing countries. The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term.”

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The pharma company reported 79% jump in consolidated net profit to Rs 939.04 crore on 10% increase in revenue from operations to Rs 6,163 core in Q4 FY24 over Q4 FY23.

The scrip hit an all time high of Rs 1,576.45 in today’s intraday session.

Previous News
  Cipla Ltd spurts 0.42%, up for fifth straight session
 ( Hot Pursuit - 11-Jun-25   13:00 )
  Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany
 ( Corporate News - 29-May-25   18:50 )
  Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen
 ( Corporate News - 29-May-25   18:48 )
  Cipla
 ( Results - Analysis 14-May-25   10:22 )
  Cipla to convene AGM
 ( Corporate News - 14-May-25   15:08 )
  Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%
 ( Hot Pursuit - 13-May-25   15:17 )
  Board of Cipla recommends final dividend
 ( Corporate News - 13-May-25   14:34 )
  Board of Cipla recommends special dividend
 ( Corporate News - 13-May-25   14:34 )
  Cipla consolidated net profit rises 30.12% in the March 2025 quarter
 ( Results - Announcements 13-May-25   14:14 )
  Cipla fixes record date for final dividend
 ( Market Beat - Reports 13-May-25   13:47 )
  Cipla’s Goa API facility receives VAI status from USFDA
 ( Hot Pursuit - 21-Apr-25   11:32 )
Other Stories
  SG Mart forays into renewable energy sector with launch of APL Apollo SunSteel
  12-Jun-25   15:39
  Maithan Alloys acquires minority stake in GAIL (India) for Rs 12 cr
  12-Jun-25   15:32
  Kay Cee Energy & Infra hits the roof on securing Rs 28 cr transmission order from RVPN
  12-Jun-25   15:19
  C.E. Info Systems Ltd leads losers in 'A' group
  12-Jun-25   15:00
  Cinevista Ltd leads losers in 'B' group
  12-Jun-25   14:45
  C E Info Systems slumps after block deal
  12-Jun-25   14:45
  Ashoka Buildcon tumbles as GST notice triggers search & seizure operation
  12-Jun-25   14:43
  Happiest Minds appoints Anand Balakrishnan as chief financial officer
  12-Jun-25   14:39
  Volumes spurt at RHI Magnesita India Ltd counter
  12-Jun-25   14:30
  Crisil Ratings reaffirms ratings of Ratnamani Metals at 'AA/A1+' with 'stable' outlook
  12-Jun-25   14:25
Back Top